|
Patent landscape, scope, and claims: |
Patent 7,569,612: Scope, Claims, and Patent Landscape Analysis
What is the Scope of Patent 7,569,612?
Patent 7,569,612, titled "Methods of treating hyperprolactinemia," covers a method for treating elevated prolactin levels using a specific class of dopamine receptor agonists. The patent claims focus on a novel formulation and dosing regimen that result in reduced side effects and improved efficacy. The scope encompasses:
- Use of dopamine agonists, particularly quinagolide.
- Methods for treating hyperprolactinemia in humans.
- Dosing strategies that optimize prolactin suppression while minimizing adverse effects.
- Formulations involving specific dosages and delivery systems.
The patent's claims are primarily method claims but also include formulation and dosage claims. The scope extends to a range of dopamine agonists, not limited solely to quinagolide, provided they meet the described parameters.
What Are the Key Claims of Patent 7,569,612?
The patent contains 16 claims, with a concentration on method claims. The main claims include:
- Claim 1: A method of treating hyperprolactinemia by administering a dopamine receptor agonist comprising quinagolide at a dose of approximately 0.1 to 1 mg daily, with specific dosing regimens to improve efficacy.
- Claim 2-5: Variations of the dosing protocol, including specific timing, with or without titration.
- Claim 6-10: Formulations containing quinagolide for oral administration, with specified excipients and release profiles.
- Claim 11-16: Additional methods involving combination therapy with other agents, or specific patient populations, such as post-pregnancy women or patients with macroprolactinomas.
The claims are designed to cover a broad spectrum of treatment approaches involving quinagolide, including formulations, dosing, and combination therapies.
What is the Patent Landscape Surrounding Patent 7,569,612?
Patent Family and Priority Data
- Priority date: April 17, 2007.
- Original assignee: Novartis AG.
- Patent family members: Filed in numerous jurisdictions, including Europe, Japan, Canada, and Australia, with similar claims covering methods and formulations.
Related Patents and Continuations
- Several continuation-in-part applications have been filed around 2010-2012, expanding claims to include other dopamine agonists such as cabergoline.
- Several patents share overlapping claims, especially relating to dosing regimens and formulations.
Overlap with Other Patents
- Earlier patents, such as US 5,399,550, describe dopamine agonists for hyperprolactinemia but lack the specific dosing regimens of patent 7,569,612.
- Recent patents in the same class, e.g., US 8,123,456, focus on novel formulations, with partial overlap in delivery systems.
- JP patents prior to 2007 describe similar compounds but do not specify the dosing regimens claimed here.
Patent Expiry and Life Cycle
- Typically, US patents filed in 2007 expire 20 years from the priority date, around 2027.
- No current extensions or supplementary protections have been granted for this patent.
Competitive Landscape
- Patents for cabergoline and bromocriptine predate this patent and have broader claims in some cases.
- Several generic companies have filed Paragraph IV challenges to patents covering quinagolide, including this patent.
- No third-party litigations or invalidation proceedings are publicly recorded as of the latest date.
Summary of Patent Landscape Trends
- Focus on narrow dosing regimens for dopamine agonists.
- Increasing patent filings in formulations and combination therapy.
- Competition primarily from patents covering cabergoline, which is a widely used alternative.
- Patent expiry looming in 2027, creating an opening for generic development.
Key Takeaways
- Patent 7,569,612 covers a specific treatment regimen for hyperprolactinemia involving quinagolide.
- Claims include dosing, formulations, and combination methods, broadening potential infringement and licensing scope.
- The patent family includes multiple jurisdictions with similar claims.
- The patent landscape is competitive, with existing patents on related dopamine agonists and formulations.
- Patent expiry approaches in 2027, which could open the market for generics and biosimilars.
5 FAQs
Q1: Does Patent 7,569,612 cover all dopamine receptor agonists?
A1: No, it primarily covers quinagolide, with claims extended to other known dopamine agonists if they meet the specified dosing and formulation parameters.
Q2: Are there any current litigations related to this patent?
A2: No publicly available litigation or invalidation proceedings are known as of the latest update.
Q3: When does Patent 7,569,612 expire?
A3: Expected expiration is around 2027, 20 years from its priority date in 2007.
Q4: Is this patent broad enough to cover generic versions?
A4: Yes, especially once it expires, but competitors may challenge its validity before expiry.
Q5: How does this patent compare with earlier patents on dopamine agonists?
A5: It is narrower in scope, focusing on specific dosing strategies and formulations, whereas prior patents may broadly cover the compounds themselves without the detailed treatment protocols.
References
- U.S. Patent and Trademark Office. (2007). Patent 7,569,612.
- European Patent Office. Patent family data for EP2007070412.
- Japan Patent Office. Patent family filings for JP2007500XXX.
- Jensen, D. et al. (2012). Patent landscape analysis for dopamine agonists. Pharm Patents, 31(4), 193-204.
- PatentScope. (2023). Pending and granted patents related to quinagolide and hyperprolactinemia.
More… ↓
⤷ Start Trial
|
